DEA moves some CBD medicines off Schedule 1, a limited expansion of cannabis access

A sheet of cannabis marijuana in the defocus with the image of the formula CBD

The U.S. Drug Enforcement Administration has taken some cannabidiol out of the most restrictive class of controlled substances, a move that allows the sale of the first nonsynthetic, cannabis-derived medicine to win federal approval.

It’s a decision that immediately affects CBD producers but also signals the agency’s first admission that the plant has medical value.

The DEA announced Thursday that drugs including CBD with THC content below 0.1% are now considered Schedule 5 drugs, as long as they have been approved by the U.S. Food and Drug Administration.

It is the first time the agency has lowered any type of cannabis from Schedule 1.

Continue reading “DEA moves some CBD medicines off Schedule 1, a limited expansion of cannabis access”

For Baby Boomers, 2018 Was The Year Of CBD. Get Ready For 2019

cbdizzle

2018 was the year CBD was on everyone’s lips, thanks to plenty of media buzz and the suddenly-ubiquitous presence of an array of CBD-infused beverages, lotions and self-care products. It was also the year “CBD gummies” reached No. 3 on Google’s most popular search terms. And I’m willing to go out on a limb that a significant portion of those searches were made by Baby Boomers.

Cannabidiol (CBD), a non-intoxicating compound found in cannabis, is being touted as a natural remedy for chronic pain, insomnia, depression and anxiety, among other conditions. The research to prove CBD’s therapeutic outcomes is still largely forthcoming. But even without the science, it’s no wonder that adults over 50, who suffer most from these conditions, are behind one of the fastest growing market segments for CBD products.

Continue reading “For Baby Boomers, 2018 Was The Year Of CBD. Get Ready For 2019”

Merry Christmas: Hemp and Hemp-Based CBD Are Now Legal

hemp-580x440

This has been a transformational year for the cannabis industry, one that investors will possibly never forget. Although it’s been a bit rough on the investment front, with the Horizons Marijuana Life Sciences ETF, a basket of more than four dozen pot stocks, losing approximately 40% of its value, 2018 has been a year of gained validity for the cannabis industry.

Continue reading “Merry Christmas: Hemp and Hemp-Based CBD Are Now Legal”

Does the 2018 Farm Bill Legalize CBD in all 50 States or Not?

cr health

After the U.S. House and Senate easily passed the $867 billion 2018 Farm Bill, headlines began cropping up immediately about the language within that officially ends decades of senseless prohibition of the hemp plant.

Continue reading “Does the 2018 Farm Bill Legalize CBD in all 50 States or Not?”

The Pot Stocks Are Soaring Again After a CBD-Based Drug Took a Step Closer to Commercial Launch

Marijuana stocks ripped higher Thursday after the U.S. Drug Enforcement Administration classified a cannabidiol-based drug made by GW Pharmaceuticals in its least restrictive category, setting the stage for commercial launch.

Continue reading “The Pot Stocks Are Soaring Again After a CBD-Based Drug Took a Step Closer to Commercial Launch”

Morgan Stanley: DEA Likely To Reclassify GW Pharma’s Cannabinoid Therapy For US Launch

gw

By Sunday night, the U.S. Drug Enforcement Administration is expected to reclassify GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)’s Epidiolex to allow medicinal use. This could open the therapy to a new and promising market.

Continue reading “Morgan Stanley: DEA Likely To Reclassify GW Pharma’s Cannabinoid Therapy For US Launch”

California Bans Hemp-Derived CBD Oil

Texas-CBD-Oil

California health authorities dealt a blow to the burgeoning CBD industry by banning preparations of CBD derived from industrial hemp rather than psychoactive cannabis. The decree adds to the legal confusion around the cannabinoid and highlights the need for greater clarity from authorities at both the state and federal level.

Continue reading “California Bans Hemp-Derived CBD Oil”